ACC: Promus Element remains comparable with Xience V at two years Cardiovascular Business CHICAGO—The outcomes reported at 12 months comparing the safety and effectiveness of the Promus Element everolimus-eluting platinum chromium stent to Xience V, or Promus original, everolimus-eluting stent, remained comparable at two years, ... |
